5 Apr 2018 07:00
Tiziana Life Sciences plc
("Tiziana" or the "Company")
Appointment of Broker
Tiziana Life Sciences plc (AIM: TILS), a clinical stage biotechnology company developing targeted drugs for cancer and autoimmune diseases, today announces that in order to fulfil the requirements of AIM Rule 35 (appointment of a broker) the Company has appointed Cairn Financial Advisers LLP as its broker, on an interim basis, with immediate effect.
This appointment allows the Company to fulfil its Rule 35 obligations whilst it finalises the appointment of a specialist healthcare broker, at which point Cairn Financial Advisers LLP will cease to act as the Company's broker.
Contacts
Tiziana Life Sciences plc Gabriele Cerrone, Chairman and founder
| +44 (0)20 7493 2853 |
Cairn Financial Advisers LLP (Nominated Adviser/Broker) Liam Murray / Jo Turner
| +44 (0)20 7213 0880 |
About Tiziana
Tiziana is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. The Company is focused on its lead compound milciclib. The Company is also in clinical development of foralumab. Foralumab is the only fully human engineered human anti-CD3 antibody in clinical development. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBS), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.
For more information go to http://www.tizianalifesciences.com